Anticancer therapeutic strategies based on CDK inhibitors
Luca Esposito1, Paola Indovina, Flora Magnotti
1INT-CROM, Pascale Foundation National Cancer Institute-Cancer Research Center, Mercogliano, Italy.
Current Pharmaceutical Design
|February 12, 2013
Summary
Cyclin-dependent kinase (CDK) inhibitors are crucial for cancer therapy. This review explores new therapeutic strategies using CDK inhibitors to target cancer cells effectively.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Normal cell cycle progression relies on cyclin-dependent kinases (CDKs) and cyclins.
- Cell cycle deregulation is a hallmark of cancer, often due to mutations in CDK pathways.
- CDKs are critical targets for developing novel cancer therapeutics.
Purpose of the Study:
- To review emerging therapeutic strategies utilizing cyclin-dependent kinase (CDK) inhibitors in cancer treatment.
- To discuss the role of CDK inhibitors as targeted therapies for various cancers.
Main Methods:
- Review of current literature on CDK inhibitors in cancer therapy.
- Analysis of clinical trial data for CDK inhibitors.
- Discussion of ATP-competitive and non-ATP-competitive CDK inhibitors.
Main Results:
- CDK inhibitors, both ATP-competitive and non-ATP-competitive, show promise in targeted cancer therapy.
- Clinical trials are evaluating CDK inhibitors as single agents and in combination therapies.
- Mutations in CDK pathways are common in cancer cells, highlighting their therapeutic potential.
Conclusions:
- CDK inhibitors represent a significant advancement in targeted cancer therapy.
- Further research and clinical trials are essential to optimize the use of CDK inhibitors.
- Targeting cell cycle regulation via CDK inhibition offers a promising avenue for future cancer treatments.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...